期刊
CELLS
卷 8, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/cells8101162
关键词
miRNA; COPD; cancer; survival
类别
资金
- Deutsche Krebshilfe [111450]
- Competence Network Asthma/COPD - German Federal Ministry of Education and Research [FKZ 01GI1001]
- AstraZeneca GmbH
- Bayer Schering, Pharma AG
- Chiesi GmbH
- GlaxoSmithKline
- Grifols Deutschland GmbH
- MSD Sharp Dohme GmbH
- Mundipharma GmbH
- Novartis Deutschland GmbH
- Pfizer Pharma GmbH
Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of death, reducing life expectancy on average between 5 and 7 years. The survival time after diagnosis, however, varies considerably as a result of the heterogeneity of COPD. Therefore, markers that predict individual survival of COPD patients are of great value. We analyzed baseline molecular profiles and collected 54 months of follow-up data of the cohort study COPD and SYstemic consequences-COmorbidities NETwork (COSYCONET). Genome-wide microRNA signatures from whole blood collected at time of the inclusion in the study were generated for 533 COPD patients including patients that deceased during the 54-month follow-up period (n = 53) and patients that survived this period (n = 480). We identified two blood-born microRNAs (miR-150-5p and miR-320b) that were highly predictive for survival of COPD patients. The expression change was then confirmed by RT-qPCR in 245 individuals. Ninety percent of patients with highest expression of miR-150-5p survived the 54-month period in contrast to only 50% of patients with lowest expression intensity. Moreover, the abundance of the oncogenic miR-150-5p in blood of COPD patients was predictive for the development of cancer. Thus, molecular profiles measured at the time of a COPD diagnosis have a high predictive power for the survival of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据